CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, will release its first quarter 2007 financial results on Wednesday, May 2, before the market opens. The Company will also hold a conference call at 10:00 a.m. Eastern on the 2nd to discuss the financial results, progress of its therapeutic product development programs, and additional corporate activities. Daniel Passeri, President and CEO of Curis, will host the call.
To access the live conference call, please call (800) 202-4367 from the United States and Canada or (617) 213-8845 from additional International locations, shortly before 10:00 A.M. The conference ID number is 25653838. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Wednesday, May 16, 2007. To access the replay, please call (888) 286-8010 from the United States and Canada or (617) 801-6888 from other locations and reference the conference ID number 29240402.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease, hair growth regulation and cardiovascular disease. For more information, visit www.curis.com.
CONTACT: Curis, Inc.
Michael P. Gray, 617-503-6632
For Curis, Inc
Jenny Viscarolasaga, 617-503-6658
SOURCE: Curis, Inc.